Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Melbourne University and Bio Farma to Jointly Develop Vaccine Adjuvant

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Agreement to develop a vaccine delivery system that can boost the vaccine effectiveness for a range of infectious diseases.

Melbourne University has announced an agreement with Indonesian vaccine maker Bio Farma to develop a vaccine delivery system that can boost the vaccine effectiveness for a range of infectious diseases, including Hepatitis C, Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemopilus influenza type-B.

"Bio Farma is proud to collaborate with the University of Melbourne. This agreement will surely give us an opportunity to enhance our research capacity," said Iskandar, the President Director of Bio Farma.

Iskandar expressed hope in the future of the collaboration on a vaccine delivery system to boost vaccine effectiveness (vaccine adjuvant) which would lead into a real contribution in the prevention of communicable disease in the world.

Under the proposed arrangement, Melbourne University receives research funding to further evaluate and develop a proof of concept.

The research agreement was facilitated by UoM Commercial Ltd, the University's Commercial Engagement Service company and signed on 3 September 2012.

According to Iskandar, the collaboration with Melbourne University will run for 18 months as presently the research is still in the level of proof of concept.

Upon getting a result, the next step will be enhanced to a technology license level.

Professor James Angus, Dean of the Faculty of Medicine, Dentistry and Health Sciences at Melbourne University, remarked that he was delighted to be collaborating with the Board of Bio Farma and its scientific team in relation to developing a novel vaccine platform.

The vaccine platform would lead to better and more efficacious vaccines against infectious diseases. "This agreement reflects the desire for research at the University of Melbourne to be translated into impact and recognizes the importance of collaboration with leading vaccine companies to achieve this goal," said Professor Angus.

Research led by Professor David Jackson's team in the Department of Microbiology and Immunology at the University of Melbourne has shown that a synthetic TLR2 agonist-based adjuvant can enhance immunity and protect animals from viral and bacterial infections.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Typhoid Gene Unravelled
Natural resistance against typhoid fever is linked to a particular form of the HLA-DRB1 gene.
Tuesday, November 11, 2014
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Antibody Drug Shows Promise in HIV Treatment
Researchers are a step closer to an alternative HIV treatment that has the potential for lasting effects and less frequent dosing.
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!